Cancer

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Salinomycin, Amitriptyline, Temozolomide, Berberine, Rosuvastatin and 17-DMAG (SATBRD) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 29/November/2017, 10.29 pm
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Salinomycin, Amitriptyline, Temozolomide, Berberine, Rosuvastatin and 17-DMAG (SATBRD) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 29/November/2017, 10.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more

Natural product-derived therapy for Metastatic human tumors: Andrographolide, isolated from herb Andrographis Paniculata, decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via up regulation of its target gene, 28/November/2017, 11.14 pm
Natural product-derived therapy for Metastatic human tumors: Andrographolide, isolated from herb Andrographis Paniculata, decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via up regulation of its target gene, 28/November/2017, 11.14 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102,…

read more

Natural product-based combination therapy targeting cancer stem cells in Myeloid leukaemia (ML): A therapeutic mix encompassing Pseudolaric acid B, Rosiglitazone, Ivermectin, Dacogen (PRID) inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML via up-regulation of its target gene, 25/November/2017, 4.13 pm
Natural product-based combination therapy targeting cancer stem cells in Myeloid leukaemia (ML): A therapeutic mix encompassing Pseudolaric acid B, Rosiglitazone, Ivermectin, Dacogen (PRID) inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML via up-regulation of its target gene, 25/November/2017, 4.13 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction to what they say: A study from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany; Division of Stem Cells and Cancer, German…

read more

Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing Calcitriol, Mitoxantrone, Despiramine, 17-DMAG, Salinomycin, Lovastatin, and Jasmonate (CMDDSLJ) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 23/November/2017, 12.15 pm
Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing Calcitriol, Mitoxantrone, Despiramine, 17-DMAG, Salinomycin, Lovastatin, and Jasmonate (CMDDSLJ) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 23/November/2017, 12.15 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.” This…

read more

Molecular therapy for glioblastoma: A therapeutic mix encompassing Temozolomide (TMZ), 17-AAG, Simvastatin, Salinomycin, Linalool, Amitriptyline (TASSLA) inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 22/November/2017, 6.06 am
Molecular therapy for glioblastoma: A therapeutic mix encompassing Temozolomide (TMZ), 17-AAG, Simvastatin, Salinomycin, Linalool, Amitriptyline (TASSLA) inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 22/November/2017, 6.06 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors represent in vivo cancer…

read more

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing   β-cryptoxanthin (BCX), Sodium butyrate, Fucoxanthin, Ganetespib, Rosuvastatin and Cyclophosphamide (BCXSFGRC) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 21/November/2017, 10.49 pm
Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing   β-cryptoxanthin (BCX), Sodium butyrate, Fucoxanthin, Ganetespib, Rosuvastatin and Cyclophosphamide (BCXSFGRC) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 21/November/2017, 10.49 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge,…

read more
Start Typing